Pitcairn Co. Increases Holdings in Shire PLC (SHPG)
Pitcairn Co. raised its position in shares of Shire PLC (NASDAQ:SHPG) by 26.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,917 shares of the biopharmaceutical company’s stock after buying an additional 401 shares during the quarter. Pitcairn Co.’s holdings in Shire PLC were worth $293,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in SHPG. Hartford Financial Management Inc. raised its stake in Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares in the last quarter. YorkBridge Wealth Partners LLC raised its stake in Shire PLC by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Shire PLC during the second quarter valued at approximately $171,000. Stephens Inc. AR raised its stake in Shire PLC by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares in the last quarter. Finally, Ingalls & Snyder LLC raised its stake in Shire PLC by 10.8% during the second quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 19.24% of the company’s stock.
Several analysts have issued reports on SHPG shares. Cantor Fitzgerald restated a “buy” rating and set a $222.00 price objective on shares of Shire PLC in a research note on Monday, August 21st. BTIG Research restated a “buy” rating and set a $242.00 price objective on shares of Shire PLC in a research note on Monday, July 17th. Royal Bank Of Canada set a $213.00 price objective on Shire PLC and gave the company a “buy” rating in a research note on Friday, August 4th. Stifel Nicolaus restated a “buy” rating and set a $245.00 price objective on shares of Shire PLC in a research note on Sunday, October 8th. Finally, FBR & Co started coverage on Shire PLC in a research note on Thursday, October 19th. They set a “buy” rating and a $201.00 price objective on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $211.00.
COPYRIGHT VIOLATION NOTICE: “Pitcairn Co. Increases Holdings in Shire PLC (SHPG)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/12/pitcairn-co-increases-holdings-in-shire-plc-shpg.html.
Shares of Shire PLC (NASDAQ SHPG) traded up $0.29 during mid-day trading on Friday, reaching $140.36. The company had a trading volume of 701,000 shares, compared to its average volume of 1,228,033. Shire PLC has a 1-year low of $137.80 and a 1-year high of $192.15. The company has a market cap of $42,151.51, a price-to-earnings ratio of 9.65, a price-to-earnings-growth ratio of 0.78 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion during the quarter. During the same period last year, the company earned $3.17 earnings per share. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. sell-side analysts forecast that Shire PLC will post 15 EPS for the current fiscal year.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.